Total Payments
$45,702
2024 Payments
$3,480
Companies
50
Transactions
1,445
Medicare Patients
1,569
Medicare Billing
$196,663
Payment Breakdown by Category
Research$23,436 (51.3%)
Food & Beverage$20,739 (45.4%)
Consulting$1,295 (2.8%)
Education$232.15 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23,436 | 4 | 51.3% |
| Food and Beverage | $20,739 | 1,427 | 45.4% |
| Consulting Fee | $1,295 | 1 | 2.8% |
| Education | $232.15 | 13 | 0.5% |
Payments by Type
Research
$23,436
4 transactions
General
$22,266
1,441 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $23,436 | 4 | $0 (2022) |
| Amgen Inc. | $4,172 | 285 | $0 (2024) |
| UCB, Inc. | $2,955 | 122 | $0 (2024) |
| ABBVIE INC. | $2,210 | 142 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,587 | 142 | $0 (2024) |
| PFIZER INC. | $1,403 | 112 | $0 (2024) |
| Janssen Biotech, Inc. | $1,102 | 76 | $0 (2024) |
| GlaxoSmithKline, LLC. | $928.86 | 68 | $0 (2024) |
| Lilly USA, LLC | $908.08 | 57 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $894.35 | 53 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,480 | 241 | Amgen Inc. ($838.17) |
| 2023 | $3,663 | 235 | Amgen Inc. ($835.02) |
| 2022 | $3,610 | 236 | Amgen Inc. ($422.62) |
| 2021 | $2,594 | 167 | Amgen Inc. ($495.64) |
| 2020 | $4,774 | 158 | UCB, Inc. ($1,421) |
| 2019 | $24,134 | 142 | Eli Lilly and Company ($22,096) |
| 2018 | $1,471 | 109 | Amgen Inc. ($303.11) |
| 2017 | $1,976 | 157 | Amgen Inc. ($261.13) |
All Payment Transactions
1,445 individual payment records from CMS Open Payments — Page 1 of 58
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $8.38 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $9.62 | General |
| 12/16/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $9.80 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | Fresenius Kabi USA, LLC | Tyenne (Biological) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Biosimilars | ||||||
| 12/05/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Rheumatology | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $9.13 | General |
| Category: Immunology | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $2.97 | General |
| Category: Immunology | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/18/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $8.94 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/14/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $12.18 | General |
| Category: Bone Health | ||||||
| 11/12/2024 | Organon Llc | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: INFLIXIMAB | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $22,509 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $927.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 476 | 731 | $197,807 | $60,281 |
| 2022 | 8 | 393 | 633 | $186,671 | $60,369 |
| 2021 | 6 | 288 | 475 | $127,982 | $34,913 |
| 2020 | 8 | 412 | 728 | $117,523 | $41,101 |
Total Patients
1,569
Total Services
2,567
Medicare Billing
$196,663
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 36 | 36 | $11,465 | $4,336 | 37.8% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2020 | 23 | 52 | $10,647 | $3,128 | 29.4% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2020 | 14 | 15 | $2,169 | $782.45 | 36.1% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2020 | 40 | 84 | $1,956 | $663.97 | 33.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 35 | 47 | $1,309 | $453.70 | 34.7% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2020 | 23 | 28 | $337.06 | $116.37 | 34.5% |
About Dr. Priya Ramani, M.D
Dr. Priya Ramani, M.D is a Rheumatology healthcare provider based in Oldsmar, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093779712.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Priya Ramani, M.D has received a total of $45,702 in payments from pharmaceutical and medical device companies, with $3,480 received in 2024. These payments were reported across 1,445 transactions from 50 companies. The most common payment nature is "" ($23,436).
As a Medicare-enrolled provider, Ramani has provided services to 1,569 Medicare beneficiaries, totaling 2,567 services with total Medicare billing of $196,663. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Oldsmar, FL
- Active Since 04/12/2006
- Last Updated 02/10/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1093779712
Products in Payments
- Enbrel (Biological) $2,431
- Cimzia (Drug) $1,595
- XELJANZ (Drug) $1,304
- ACTHAR (Biological) $1,167
- COSENTYX (Biological) $1,051
- BENLYSTA (Biological) $918.47
- TALTZ (Drug) $833.88
- RINVOQ (Biological) $702.37
- KRYSTEXXA (Biological) $660.61
- LUPKYNIS (Drug) $619.49
- EVENITY (Biological) $609.98
- Humira (Biological) $567.58
- ORENCIA (Biological) $549.53
- COSENTYX (Drug) $476.45
- OFEV (Drug) $455.68
- TREMFYA (Drug) $451.91
- KEVZARA (Drug) $418.53
- REMICADE (Biological) $389.76
- SAPHNELO (Biological) $388.01
- RINVOQ (Drug) $324.42
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.